The launch of Wegovy by Novo Nordisk in the United States as the first-ever oral GLP-1 medication for treating obesity, as well as the advancement of orforglipron by Eli Lilly, will affect competition, as companies strive to develop more convenient and better-tolerated medications that can provide good payer value
We hope this has helped you make up on your mind when considering a treatment
Factors like energy density, viscosity, and moisture content significantly influence gastric emptying, which in turn affects digestion, satiety, and the severity of GI symptoms [60]
By fostering open communication with healthcare professionals and adhering to recommended guidelines, individuals can enjoy social occasions while prioritizing their health
According to Mintel, the use of GLP-1 drugs continues to climb, rising from 12 percent adoption to 18 percent in just over a year in the United States alone